← Leaderboards
Molly Forrest Franke
Harvard School Of Public Health
$11,435,450
Attributed
$38,782,386
Total exposure
14
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.5M · FY2007–25$10M$7.5M$5M$2.5M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$38,744,586 · 13
CDC$37,800 · 1
By mechanism
U19$30,881,052 · 7
R01$7,084,179 · 3
R21$440,814 · 1
R03$338,541 · 2
R36$37,800 · 1
Top collaborators
- Darrell P Chandler31 shared
- Aedin C Culhane31 shared
- Jerome Timothy Galea31 shared
- Anne Goldfeld31 shared
- Louise Catherine Ivers31 shared
- Ann Chesney Miller31 shared
- Nira Pollock31 shared
- Eric Joseph Rubin31 shared
Others in their field
Top investigators on “Diagnosis”
- David Heimbrook · Leidos Biomedical Research, Inc.$590,717,255
- Bambra Strokes · Ppd Development Lp$526,656,217
- Leonard Freedman · Leidos Biomedical Research, Inc.$337,858,596
- Richard K. Wilson · Washington University$297,645,172
- Sharon A Nachman · Johns Hopkins University$212,395,175
- Carol Nesel · Westat$188,148,170
Research focus
DiagnosisBaseDiagnosticInnovationPeruMycobacterium TuberculosisDiagnostic TestsCostDrug ResistancePharmaceutical PreparationsTuberculosisProgramsChildhoodDesignResistanceDrug Resistance In TuberculosisEnsureTransmission ProcessChildMorbidity - Disease RateRegimenAdultDetectionSampling
Grant awards (53)
Efficacy of a differentiated care intervention for adolescents transitioning to adult HIV care in Peru$453,918
R01 · FY2025 · MH · contact PI
Efficacy of a differentiated care intervention for adolescents transitioning to adult HIV care in Peru$206,856
R01 · FY2025 · MH · contact PI
Understanding the mediating role of adherence in risk factors for unfavorable outcomes from tuberculosis treatment$84,750
R03 · FY2025 · AI · contact PI
Strengthening evidence on optimal multidrug-resistant tuberculosis treatment regimens through improved epidemiologic methods$739,542
R01 · FY2024 · AI · contact PI
Efficacy of a differentiated care intervention for adolescents transitioning to adult HIV care in Peru$652,509
R01 · FY2024 · MH · contact PI
Feasibility of a community-engaged social marketing strategy to reduce HIV-related stigma and improve health among young people$150,699
R01 · FY2024 · TW · contact PI
Efficacy of a differentiated care intervention for adolescents transitioning to adult HIV care in Peru$100,000
R01 · FY2024 · MH · contact PI
Understanding the mediating role of adherence in risk factors for unfavorable outcomes from tuberculosis treatment$84,750
R03 · FY2024 · AI · contact PI
Strengthening evidence on optimal multidrug-resistant tuberculosis treatment regimens through improved epidemiologic methods$723,588
R01 · FY2023 · AI · contact PI
Efficacy of a differentiated care intervention for adolescents transitioning to adult HIV care in Peru$650,139
R01 · FY2023 · MH · contact PI
Feasibility of a community-engaged social marketing strategy to reduce HIV-related stigma and improve health among young people$269,183
R01 · FY2023 · TW · contact PI
Efficacy of a differentiated care intervention for adolescents transitioning to adult HIV care in Peru$802,879
R01 · FY2022 · MH · contact PI
Strengthening evidence on optimal multidrug-resistant tuberculosis treatment regimens through improved epidemiologic methods$685,092
R01 · FY2022 · AI · contact PI
Feasibility of a community-engaged social marketing strategy to reduce HIV-related stigma and improve health among young people$211,407
R01 · FY2022 · TW · contact PI
Strengthening evidence on optimal multidrug-resistant tuberculosis treatment regimens through improved epidemiologic methods$702,282
R01 · FY2021 · AI · contact PI
Detection of transrenal Mycobacterium tuberculosis DNA in urine$84,541
R03 · FY2021 · AI · contact PI
Strengthening evidence on optimal multidrug-resistant tuberculosis treatment regimens through improved epidemiologic methods$736,085
R01 · FY2020 · AI · contact PI
Accompanying HIV-positive adolescents through the transition into adult care: a feasibility study$194,243
R21 · FY2020 · AI · contact PI
Detection of transrenal Mycobacterium tuberculosis DNA in urine$84,500
R03 · FY2020 · AI · contact PI
Clinical Studies$880,673
U19 · FY2019 · AI · contact PI
Accompanying HIV-positive adolescents through the transition into adult care: a feasibility study$246,571
R21 · FY2019 · AI · contact PI
Sequencing Core$2,595,356
U19 · FY2018 · AI
Genetic determinants of drug resistance in Mycobacteria tuberculosis$1,274,314
U19 · FY2018 · AI
Discovery and validation of drug resistance mutations$938,261
U19 · FY2018 · AI
Innovative Strategies to Improve Tuberculosis Diagnostics in Children$888,730
U19 · FY2018 · AI · contact PI
Administrative Core$412,046
U19 · FY2018 · AI
Integrated system for Category C infectious disease diagnostics in resource-limi$403,448
U19 · FY2018 · AI
Integrated system for Category C infectious disease diagnostics in resource-limi$2,182,203
U19 · FY2017 · AI
Innovative Strategies to Improve Tuberculosis Diagnostics in Children$1,095,803
U19 · FY2017 · AI · contact PI
Genetic determinants of drug resistance in Mycobacteria tuberculosis$913,253
U19 · FY2017 · AI
Discovery and validation of drug resistance mutations$734,112
U19 · FY2017 · AI
Administrative Core$616,131
U19 · FY2017 · AI
Sequencing Core$408,777
U19 · FY2017 · AI
Integrated system for Category C infectious disease diagnostics in resource-limi$2,528,705
U19 · FY2016 · AI
Innovative Strategies to Improve Tuberculosis Diagnostics in Children$992,134
U19 · FY2016 · AI · contact PI
Discovery and validation of drug resistance mutations$750,894
U19 · FY2016 · AI
Genetic determinants of drug resistance in Mycobacteria tuberculosis$715,308
U19 · FY2016 · AI
Sequencing Core$421,675
U19 · FY2016 · AI
Administrative Core$410,524
U19 · FY2016 · AI
Genetic determinants of drug resistance in Mycobacteria tuberculosis$82,633
U19 · FY2016 · AI
Integrated system for Category C infectious disease diagnostics in resource-limi$2,500,809
U19 · FY2015 · AI
Innovative Strategies to Improve Tuberculosis Diagnostics in Children$932,090
U19 · FY2015 · AI · contact PI
Discovery and validation of drug resistance mutations$774,241
U19 · FY2015 · AI
Sequencing Core$660,525
U19 · FY2015 · AI
Genetic determinants of drug resistance in Mycobacteria tuberculosis$500,331
U19 · FY2015 · AI
Administrative Core$311,434
U19 · FY2015 · AI
Integrated system for Category C infectious disease diagnostics in resource-limi$2,916,905
U19 · FY2014 · AI
Innovative Strategies to Improve Tuberculosis Diagnostics in Children$900,727
U19 · FY2014 · AI · contact PI
Sequencing Core$822,385
U19 · FY2014 · AI
Discovery and validation of drug resistance mutations$554,926
U19 · FY2014 · AI
Genetic determinants of drug resistance in Mycobacteria tuberculosis$536,059
U19 · FY2014 · AI
Administrative Core$225,640
U19 · FY2014 · AI
Helminth infection and the risk of tuberculosis in children$37,800
R36 · FY2007 · PS · contact PI